Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata referenced "SELLAS Life Sciences," but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Reporting Period: Fiscal year ended December 31, 2010.
Business Overview: RXi is a development-stage biotechnology company focused on RNA interference (RNAi) and immunotherapy technologies. The company has no product revenue to date. Its primary activities involve the discovery and pre-clinical development of therapeutic candidates.
Strategic Shift: In April 2011 (subsequent to the reporting period), RXi acquired Apthera, Inc., adding the late-stage breast cancer immunotherapy candidate NeuVax to its pipeline. This acquisition significantly altered the company's strategic focus from purely RNAi discovery to a dual-platform approach including advanced immunotherapy.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(11,993,000) | $(18,387,000) |
| Research & Development Expense | $7,873,000 | $8,892,000 |
| General & Administrative Expense | $8,752,000 | $8,628,000 |
| Cash and Cash Equivalents (Year End) | $6,891,000 | $5,684,000 |
| Net Cash Used in Operating Activities | $(10,257,000) | $(11,769,000) |
| Net Cash Provided by Financing Activities | $11,570,000 | $7,680,000 |
| Total Assets | $7,476,000 | $6,252,000 |
| Total Liabilities | $5,046,000 | $5,511,000 |
Debt and Liquidity: The company has minimal debt, consisting primarily of capital lease obligations ($71,000 total). Liquidity is driven by cash reserves and equity financing. As of December 31, 2010, cash was approximately $6.9 million. Management estimated this would fund operations through the first quarter of 2012.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $6.4 million (35%) from 2009 to 2010. This improvement was primarily driven by a $5.5 million increase in "Other Income," largely due to a $3.0 million gain from the change in fair value of common stock warrants issued and a $785,000 reduction in potential redemption liability.
- Operating Expenses: Total operating expenses decreased slightly by $895,000. Research and Development (R&D) expenses declined by $1.0 million (11%) due to reduced non-employee stock-based compensation and timing of patent costs. General and Administrative (G&A) expenses increased marginally by $124,000 (1%), driven by higher headcount and stock-based compensation, offset by lower warrant issuance costs.
- Financing Activity: Net cash provided by financing activities increased significantly by $3.9 million, primarily due to a registered direct offering in March 2010 that raised approximately $15.2 million in net proceeds, partially offset by a $3.8 million repurchase of treasury stock.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance:
- NeuVax (Immunotherapy): Following the Apthera acquisition, the company expects to enter Phase III clinical trials for NeuVax (breast cancer) in the first half of 2012, pending FDA release from a partial clinical hold regarding Chemical Manufacturing and Controls (CMC) information. Estimated cost to resolve CMC issues is $2.5 million.
- RXI-109 (RNAi): The company plans to file an Investigational New Drug (IND) application for RXI-109 (dermal anti-scarring) in the second half of 2011, with Phase I trials targeted for the first half of 2012.
- Capital Needs: The company anticipates significant increases in expenses due to the Apthera integration and Phase III trial costs. It expects to require additional funding through equity sales, partnerships, or grants to maintain operations beyond early 2012.
Risks and Contingencies:
- Regulatory Hold: NeuVax is subject to a partial FDA clinical hold until CMC data is submitted and accepted.
- Going Concern: The company has incurred significant losses since inception and has no revenue. Continued operations depend on securing additional financing, which is not guaranteed.
- Intellectual Property: The company relies on licensed technology (e.g., from University of Massachusetts Medical School) and faces risks regarding patent validity and potential infringement claims.
- Integration Risk: The recent acquisition of Apthera introduces risks related to integrating operations, cultures, and product pipelines.
Unusual Items:
- Warrant Fair Value Changes: A significant portion of the 2010 net income improvement was non-cash, resulting from the revaluation of derivative liabilities (warrants) recorded at fair value.
- Subsequent Financing: In March and April 2011, the company completed two public offerings raising approximately $19.3 million in gross proceeds to fund the Apthera acquisition and future clinical trials.
Investor Verification Checklist
- Regulatory Status of NeuVax: Verify the current status of the FDA partial clinical hold and the timeline for submitting CMC data required to initiate Phase III trials.
- Cash Runway: Confirm the current cash balance and burn rate post-April 2011 financings to assess the timeline for the next capital raise.
- Apthera Integration: Review the progress of integrating Apthera's management and operations, and the status of the contingent value rights (earn-out) agreement.
- License Obligations: Review the specific milestone and royalty payment obligations under the University of Massachusetts Medical School (UMMS) and other license agreements, particularly those triggered by clinical milestones.
- Derivative Liabilities: Monitor the fair value of outstanding warrants and their impact on future earnings, as fluctuations in stock price can create significant non-cash gains or losses.